Literature DB >> 1424430

Enantioselective pharmacokinetics and pharmacodynamics of dl-threo-methylphenidate in children with attention deficit hyperactivity disorder.

N R Srinivas1, J W Hubbard, D Quinn, K K Midha.   

Abstract

Nine boys with attention-deficit hyperactivity disorder took part in a study in which d-methylphenidate, l-methylphenidate, dl-methylphenidate, or placebo were administered in a double-blind, four-way, randomized, crossover design. Plasma levels of the isomers of methylphenidate were monitored by means of an enantioselective assay method. The ability of the children to perform tasks that required sustained attention was monitored by a battery of computer tests. There was no evidence of interconversion between the enantiomers in vivo, although the presence of the d-isomer significantly altered the pharmacokinetics of the l-antipode. The presence of the l-isomer did not affect the pharmacokinetics of d-methylphenidate. The computer tests revealed a drug-induced improvement in sustained attention that was entirely attributable to the d-enantiomer. There was no evidence to suggest that the effectiveness of d-methylphenidate was in any way compromised by the presence of its antipode.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1424430     DOI: 10.1038/clpt.1992.185

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  27 in total

1.  Dexmethylphenidate extended release: in attention-deficit hyperactivity disorder.

Authors:  Dean M Robinson; Gillian M Keating
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  Methylphenidate transdermal system in attention-deficit hyperactivity disorder in children: A viewpoint by Raul R. Silva.

Authors:  Raul R Silva
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 3.  Evolution of stimulants to treat ADHD: transdermal methylphenidate.

Authors:  Kennerly S Patrick; Arthur B Straughn; Jeb S Perkins; Mario A González
Journal:  Hum Psychopharmacol       Date:  2009-01       Impact factor: 1.672

4.  Association of ADHD and the Protogenin gene in the chromosome 15q21.3 reading disabilities linkage region.

Authors:  K G Wigg; Y Feng; J Crosbie; R Tannock; J L Kennedy; A Ickowicz; M Malone; R Schachar; C L Barr
Journal:  Genes Brain Behav       Date:  2008-11       Impact factor: 3.449

Review 5.  Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations.

Authors:  Catherine C Crone; Geoffrey M Gabriel
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

6.  Modulation of motorcortical excitability by methylphenidate in adult voluntary test persons performing a go/nogo task.

Authors:  Johannes Buchmann; A Dueck; W Gierow; H Zamorski; S Heinicke; H Heinrich; J Hoeppner; T Klauer; O Reis; F Haessler
Journal:  J Neural Transm (Vienna)       Date:  2009-12-10       Impact factor: 3.575

Review 7.  Dexmethylphenidate extended release: a review of its use in the treatment of attention-deficit hyperactivity disorder.

Authors:  Marit D Moen; Susan J Keam
Journal:  CNS Drugs       Date:  2009-12       Impact factor: 5.749

8.  A pharmacokinetic model of oral methylphenidate in the rat and effects on behavior.

Authors:  Panayotis K Thanos; Lisa S Robison; Jessica Steier; Yu Fen Hwang; Thomas Cooper; James M Swanson; David E Komatsu; Michael Hadjiargyrou; Nora D Volkow
Journal:  Pharmacol Biochem Behav       Date:  2015-01-29       Impact factor: 3.533

9.  Enantiospecific gas chromatographic-mass spectrometric analysis of urinary methylphenidate: implications for phenotyping.

Authors:  Natalie L LeVasseur; Hao-Jie Zhu; John S Markowitz; C Lindsay DeVane; Kennerly S Patrick
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-12-04       Impact factor: 3.205

10.  Dexmethylphenidate hydrochloride in the treatment of attention deficit hyperactivity disorder.

Authors:  Feng Liu; Haruka Minami; Raul R Silva
Journal:  Neuropsychiatr Dis Treat       Date:  2006-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.